Contact this trialFirst, we need to learn more about you.
Adrenergic Blocker
Carvedilol for Parkinson's Disease
Recruiting3 awardsPhase 2
Los Angeles, California
This trial will investigate the long-term effects of treatment with the adrenergic blocker carvedilol on dopamine transporter (DAT) single photon emission computerized tomography (SPECT) imaging in people with defined pre-motor Parkinson's disease risks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service